AXL-targeted ADCs have been evaluated in non-small-cell lung cancer,75 soft tissue sarcoma,76 and melanoma,77 in combination with small molecule inhibitors or immune checkpoint blockade,78 and Phase I clinical trials with ADCT-601 are ongoing (NCT05389462). Here, AXL is linked to soft tissue sarcoma.